CN114269747A - 一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用 - Google Patents

一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用 Download PDF

Info

Publication number
CN114269747A
CN114269747A CN202080053796.0A CN202080053796A CN114269747A CN 114269747 A CN114269747 A CN 114269747A CN 202080053796 A CN202080053796 A CN 202080053796A CN 114269747 A CN114269747 A CN 114269747A
Authority
CN
China
Prior art keywords
compound
alkyl
group
independently
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080053796.0A
Other languages
English (en)
Other versions
CN114269747B (zh
Inventor
张玲
蒋钰
唐演
周珺
金雪梅
万泽红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Enhua Biomedical Technology Co ltd
Original Assignee
Suzhou Enhua Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Enhua Biomedical Technology Co ltd filed Critical Suzhou Enhua Biomedical Technology Co ltd
Publication of CN114269747A publication Critical patent/CN114269747A/zh
Application granted granted Critical
Publication of CN114269747B publication Critical patent/CN114269747B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种1′，2′‑二氢‑3′H‑螺[环丁烷1，4′‑异喹啉]‑3′‑酮衍生物及其应用，其具有式(A)所示结构，该类化合物可用于制备治疗神经精神类疾病的药物，

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080053796.0A 2019-11-18 2020-11-18 一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用 Active CN114269747B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911133562 2019-11-18
CN2019111335622 2019-11-18
CN202010198664 2020-03-20
CN2020101986649 2020-03-20
PCT/CN2020/129826 WO2021098732A1 (zh) 2019-11-18 2020-11-18 一种1',2'-二氢-3'h-螺[环丁烷1,4'-异喹啉]-3'-酮衍生物及其应用

Publications (2)

Publication Number Publication Date
CN114269747A true CN114269747A (zh) 2022-04-01
CN114269747B CN114269747B (zh) 2023-04-18

Family

ID=75979943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053796.0A Active CN114269747B (zh) 2019-11-18 2020-11-18 一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用

Country Status (2)

Country Link
CN (1) CN114269747B (zh)
WO (1) WO2021098732A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104903313A (zh) * 2012-10-16 2015-09-09 爱尔兰詹森科学公司 Rsv抗病毒化合物
CN106957285A (zh) * 2012-12-04 2017-07-18 皮埃尔法布雷医药公司 氨基环丁烷衍生物、其制备方法及其用作药物的用途
WO2018038667A1 (en) * 2016-08-25 2018-03-01 Medivir Ab Respiratory syncytial virus inhibitors
CN107922407A (zh) * 2015-07-30 2018-04-17 美迪维尔公司 呼吸道合胞病毒抑制剂
CN108349942A (zh) * 2015-11-06 2018-07-31 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015102929A1 (en) * 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104903313A (zh) * 2012-10-16 2015-09-09 爱尔兰詹森科学公司 Rsv抗病毒化合物
CN106957285A (zh) * 2012-12-04 2017-07-18 皮埃尔法布雷医药公司 氨基环丁烷衍生物、其制备方法及其用作药物的用途
CN107922407A (zh) * 2015-07-30 2018-04-17 美迪维尔公司 呼吸道合胞病毒抑制剂
CN108349942A (zh) * 2015-11-06 2018-07-31 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
WO2018038667A1 (en) * 2016-08-25 2018-03-01 Medivir Ab Respiratory syncytial virus inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY: "CAS：1782636-83-2，1782893-91-7，1936378-91-4，89192-70-1，1547297-66-4" *

Also Published As

Publication number Publication date
WO2021098732A1 (zh) 2021-05-27
CN114269747B (zh) 2023-04-18

Similar Documents

Publication Publication Date Title
BR112020024470A2 (pt) agonistas do receptor de glp-1 e seus usos
JP7074674B2 (ja) Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
TW201718558A (zh) 氧雜螺環類衍生物、其製備方法及其在醫藥上的應用
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
KR20150110787A (ko) 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EP2951185A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
US20230331720A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
JP2019532077A (ja) 治療用化合物及びその使用方法
CA3103929A1 (en) Phenyl substituted pyrazoles as modulators of roryt
US20230002366A1 (en) Indene derivatives useful in treating pain and inflammation
JP2021534215A (ja) 病的症状の治療における使用のための芳香族分子
JP2021529807A (ja) タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法
CN107207476A (zh) 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途
CN114269747B (zh) 一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用
US9688684B2 (en) Substituted tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors
WO2022135546A1 (zh) 作为kras-g12c抑制剂的螺环类化合物
EP3333165B1 (en) Piperazine derivative
EP2819999A1 (en) Spirohydantoin compounds and their use as selective androgen receptor modulators
CN115427410B (zh) 酰胺或者磺酰胺类衍生物及其应用
AU2012288457B2 (en) Pyrazoline derivatives and their use as selective androgen receptor modulators
JP2022554130A (ja) 四員環誘導体の調節剤、調製方法及びその利用
WO2019182950A1 (en) Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
WO2019057112A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
US11591289B2 (en) Aromatic compounds
CN115650902A (zh) 1′,2′-二氢-3′h-螺[环丁烷1,4′-异喹啉]-3′-酮衍生物的盐及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant